Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from:


Versions (3) ▾
  1. 6/29/17
  2. 1/10/18
  3. 1/10/18
Copyright Holder:
Antisoma Research
Uploaded on:

January 10, 2018

No DOI assigned. To request one please log in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Leukemia, Myeloid NCT00512083

Eligibility Leukemia, Myeloid NCT00512083

Inclusion Criteria
primary refractory or relapsed aml
confirmed diagnosis of aml (de novo or secondary) as defined by who classification
aged at least 18 years
Exclusion Criteria
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
patient in blast crisis stage of chronic myeloid leukemia
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
interval of <6 months between first onset of last complete remission and current relapse
those with primary refractory leukemia who have received more than three previous induction cycles
relapsed patients who have received more than three previous treatment regimens